tiprankstipranks
Advertisement
Advertisement

KYTX Stock Latest News

Kyverna’s KYSA-8 Trial Completion Puts Autoimmune Cell Therapy in Investor Focus
Company AnnouncementsKyverna’s KYSA-8 Trial Completion Puts Autoimmune Cell Therapy in Investor Focus
2d ago
KYTX
Cue Biopharma appoints Dominic Borie as chief medical officer
PremiumThe Fly
Cue Biopharma appoints Dominic Borie as chief medical officer
13d ago
CUE
KYTX
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
PremiumThe Fly
Vera chief regulatory officer William Turner to retire, Nancy Boman to succeed
17d ago
KYTX
VERA
Kyverna Therapeutics Amends Term Loan, Extends Capital Access
PremiumCompany Announcements
Kyverna Therapeutics Amends Term Loan, Extends Capital Access
17d ago
8K
KYTX
Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer
PremiumThe Fly
Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer
1M ago
KYTX
Kyverna Therapeutics: Buy Rating Reaffirmed on Strong Miv-cel RA Data and Regulatory Momentum; $33 Price Target Unchanged
PremiumRatingsKyverna Therapeutics: Buy Rating Reaffirmed on Strong Miv-cel RA Data and Regulatory Momentum; $33 Price Target Unchanged
2M ago
KYTX
Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval
Premium
Ratings
Sami Corwin Initiates Buy on Kyverna (KYTX) on Differentiated miv-cel Efficacy and Advancing BLA for First Autoimmune CAR T Approval
2M ago
KYTX
Kyverna: Buy Rating Reiterated as Emerging Clinical Profile Supports $25 Unchanged Price Target
Premium
Ratings
Kyverna: Buy Rating Reiterated as Emerging Clinical Profile Supports $25 Unchanged Price Target
2M ago
KYTX
Kyverna Therapeutics presents updated COMPARE trial data at EULAR
PremiumThe Fly
Kyverna Therapeutics presents updated COMPARE trial data at EULAR
2M ago
KYTX
Kyverna Therapeutics Stockholders Approve Directors and Auditor
PremiumCompany Announcements
Kyverna Therapeutics Stockholders Approve Directors and Auditor
2M ago
8K
KYTX
Kyverna Therapeutics Names Gregory Martini as New CFO
PremiumCompany Announcements
Kyverna Therapeutics Names Gregory Martini as New CFO
2M ago
8K
KYTX
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
PremiumThe Fly
Kyverna Therapeutics CFO Marc Grasso to step down, Greg Martini to succeed
2M ago
IRWD
KYTX
Kyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
PremiumThe FlyKyverna Therapeutics price target raised to $25 from $20 at H.C. Wainwright
2M ago
KYTX
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
Premium
The Fly
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
2M ago
KYTX
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
Premium
The Fly
Kyverna Therapeutics reports Q1 EPS (66c), consensus (73c)
2M ago
KYTX
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
PremiumThe Fly
Kyverna Therapeutics appoints Nadia Dac as chief commercial officer
3M ago
KYTX
OMER
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth
PremiumCompany Announcements
Kyverna Therapeutics Appoints Chief Commercial Officer for Growth
3M ago
8K
KYTX
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
PremiumMarket News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
3M ago
ALT
BTBT
Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target
PremiumRatings
Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target
3M ago
KYTX
Kyverna announces strong Phase 2/3 CAR T neuroimmunology data
PremiumCompany AnnouncementsKyverna announces strong Phase 2/3 CAR T neuroimmunology data
3M ago
8K
KYTX
Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome
Premium
Company Announcements
Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome
3M ago
8K
KYTX
Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel
Premium
The Fly
Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel
3M ago
KYTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >